AstraZeneca PLC Files Form 6-K
Ticker: AZN · Form: 6-K · Filed: Aug 21, 2025 · CIK: 901832
| Field | Detail |
|---|---|
| Company | Astrazeneca PLC (AZN) |
| Form Type | 6-K |
| Filed Date | Aug 21, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, foreign-issuer, routine-report
Related Tickers: AZN
TL;DR
AZN filed a 6-K, standard foreign issuer report. Nothing new, just housekeeping.
AI Summary
AstraZeneca PLC filed a Form 6-K on August 21, 2025, reporting its status as a foreign issuer. The filing indicates that AstraZeneca is submitting its reports under Form 20-F. The company's principal executive offices are located at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
Why It Matters
This filing is a routine report for foreign issuers, confirming their reporting obligations and providing updated corporate information to the SEC and investors.
Risk Assessment
Risk Level: low — This is a routine administrative filing by a foreign issuer and does not contain new material financial or operational information.
Key Players & Entities
- AstraZeneca PLC (company) — Filer of the report
- 001-11960 (company) — SEC File Number
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom (company) — Company address
- 20250821 (date) — Filing date
FAQ
What type of report is AstraZeneca PLC filing?
AstraZeneca PLC is filing a Form 6-K, which is a Report of Foreign Issuer.
When was this Form 6-K filed?
The Form 6-K was filed on August 21, 2025.
What is the SEC File Number for AstraZeneca PLC?
The SEC File Number for AstraZeneca PLC is 001-11960.
Where are AstraZeneca PLC's principal executive offices located?
AstraZeneca PLC's principal executive offices are located at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
Does AstraZeneca PLC file its annual reports under Form 20-F or Form 40-F?
AstraZeneca PLC indicates it files its annual reports under cover of Form 20-F.
Filing Stats: 1,108 words · 4 min read · ~4 pages · Grade level 9.8 · Accepted 2025-08-21 10:51:20
Filing Documents
- a2511w.htm (6-K) — 65KB
- 0001654954-25-009884.txt ( ) — 66KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.     AstraZeneca PLC     Date: 21 August 2025     By: /s/ Matthew Bowden   Name: Matthew Bowden   Title: Company Secretary